- The major counterargument would be that it seems that it also lead to numerical mortality benefit
- The counter-counterargument, which is what is for me the major limitation, is THE INTERVENTION itself - initiation AND uptitration of GMDT (and not each one of them separately):
» At the end, we still don't know if it's either th…
- The major counterargument would be that it seems that it also lead to numerical mortality benefit
- The counter-counterargument, which is what is for me the major limitation, is THE INTERVENTION itself - initiation AND uptitration of GMDT (and not each one of them separately):
» At the end, we still don't know if it's either the initiation or uptitration that is leading the benefit. If one believes that the major net benefit seen with most of the drugs in medicine comes with the lower ranges of doses (pharmacology and the evidence supports it most of the times - see and/or read the work if James McCormack and its team), one has the be convinced of the opposite with strong arguments / data.
In this trial, GMDT was both initiated and uptitrated at the same time. Would the initiation in the lower dose be enough for the benefit seen without the harm seen with more adverse events? Maybe. And we can't know it with this trial.
STRONG-HF:
- The major counterargument would be that it seems that it also lead to numerical mortality benefit
- The counter-counterargument, which is what is for me the major limitation, is THE INTERVENTION itself - initiation AND uptitration of GMDT (and not each one of them separately):
» At the end, we still don't know if it's either the initiation or uptitration that is leading the benefit. If one believes that the major net benefit seen with most of the drugs in medicine comes with the lower ranges of doses (pharmacology and the evidence supports it most of the times - see and/or read the work if James McCormack and its team), one has the be convinced of the opposite with strong arguments / data.
In this trial, GMDT was both initiated and uptitrated at the same time. Would the initiation in the lower dose be enough for the benefit seen without the harm seen with more adverse events? Maybe. And we can't know it with this trial.